SG Americas Securities
UBX

SG Americas Securities’s Unity Biotechnology UBX Stock Holding History

SG Americas Securities’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,816
Closed -$158K – 3461
2020
Q2 		$158K Buy
+1,816
New +$135K ﹤0.01% 3052
2019
Q2 		– Sell
-1,299
Closed -$105K – 3433
2019
Q1 		$105K Buy
+1,299
New +$147K ﹤0.01% 3042

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SG Americas Securities's UBX Position: Q3 2020 in Review

SG Americas Securities sold out of Unity Biotechnology (UBX) in Q3 2020, closing a stake of 1,816 shares — an estimated $158K sold.

SG Americas Securities first reported a position in UBX in Q1 2019 and held it in 2 quarters. The position peaked at $158K in Q2 2020. 79 funds tracked by Wall St. Rank hold UBX as of Q3 2020.

  • SG Americas Securities reported no remaining Unity Biotechnology position as of Q3 2020 after selling out during the quarter.
  • SG Americas Securities sold 1,816 Unity Biotechnology shares in Q3 2020, an estimated $158K.
  • SG Americas Securities first reported a position in Unity Biotechnology in Q1 2019 and held it in 2 quarters.
  • SG Americas Securities's Unity Biotechnology position peaked at $158K in Q2 2020.
  • 79 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2020.

Based on SG Americas Securities's 13F filing for Q3 2020, filed 9 Nov 2020.